Akebia Therapeutics (AKBA) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ProQR Therapeutics N.V. (PRQR) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 33.5% versus a loss of 71.4%. Over five years, AKBA leads with a -71.4% price change compared with -80.1% for PRQR. Akebia Therapeutics is the larger company by market cap ($225.8 million vs $221.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | PRQR |
|---|---|---|
| Share price | $0.8148 | $1.57 |
| Market cap | $225.79M | $221.56M |
| 1-day change | -6.71% | -3.68% |
| YTD return | -49.39% | -22.28% |
| 1-year return | -71.41% | -33.47% |
| 5-year return | -71.41% | -80.08% |
| EPS (TTM) | $-0.12 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $3.10 |
| 52-week low | $0.814 | $1.33 |
| Distance from 52-week high | -74.54% | -49.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +381.10% | +395.54% |
| Average volume | 6.18M | 796.41K |
| Shares outstanding | 277.11M | 141.12M |
| Employees | 194 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRQR has outperformed AKBA by 37.9 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
AKBA vs PRQR FAQ
Which is bigger, Akebia Therapeutics or ProQR Therapeutics N.V.?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $225.79M compared with $221.56M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, AKBA or PRQR?
PRQR returned -33.47% over the past 12 months, compared with -71.41% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.